Olaguoke Akinwande1, Meaghan Dendy2, Johannes M Ludwig2, Hyun S Kim3. 1. Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, United States. 2. Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States. 3. Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, United States; Yale Cancer Center, Yale University, New Haven, CT, United States. Electronic address: kevin.kim@yale.edu.
Abstract
PURPOSE: To systematically review the safety and efficacy of transarterial drug-eluting beads, irinotecan (DEBIRI) for the treatment of pretreated patients with unresectable colorectal liver metastases (CRLM). METHODS: A systematic search of the current literature was conducted to extract publications reporting on the use of DEBIRI for CRLM. Data on the safety and efficacy was extracted and tabulated. Weighted average values (WAV) were calculated for each variable to provide a single value representing the pooled safety and efficacy data. RESULTS: 13 studies (15 treatment arms) were evaluated, comprising a total of 850 patients. There were 6 prospective phase I/II trials, 5 retrospective trials and 2 randomized control trials. All papers involved patients previously treated with systemic chemotherapy. The weighted average all-grade toxicity rate was 35.2% (range; 6-100%). The high-grade WAV toxicity rate was 10.1% (range; 0-32%). Weighted average response rates were 56.2% and 51.1% according to RECIST (Response Evaluation Criteria in Solid Tumors) and modified RECIST/EASL (European Association for the Study of the Liver) response criteria respectively. The weighted average progression-free survival and overall survival were 8.1 months and 16.8 months, respectively. CONCLUSION: Transarterial DEBIRI is safe and effective in the treatment of unresectable CRLM to the liver. Further studies are warranted to better define its role in the treatment algorithm of this patient subset.
PURPOSE: To systematically review the safety and efficacy of transarterial drug-eluting beads, irinotecan (DEBIRI) for the treatment of pretreated patients with unresectable colorectal liver metastases (CRLM). METHODS: A systematic search of the current literature was conducted to extract publications reporting on the use of DEBIRI for CRLM. Data on the safety and efficacy was extracted and tabulated. Weighted average values (WAV) were calculated for each variable to provide a single value representing the pooled safety and efficacy data. RESULTS: 13 studies (15 treatment arms) were evaluated, comprising a total of 850 patients. There were 6 prospective phase I/II trials, 5 retrospective trials and 2 randomized control trials. All papers involved patients previously treated with systemic chemotherapy. The weighted average all-grade toxicity rate was 35.2% (range; 6-100%). The high-grade WAV toxicity rate was 10.1% (range; 0-32%). Weighted average response rates were 56.2% and 51.1% according to RECIST (Response Evaluation Criteria in Solid Tumors) and modified RECIST/EASL (European Association for the Study of the Liver) response criteria respectively. The weighted average progression-free survival and overall survival were 8.1 months and 16.8 months, respectively. CONCLUSION: Transarterial DEBIRI is safe and effective in the treatment of unresectable CRLM to the liver. Further studies are warranted to better define its role in the treatment algorithm of this patient subset.
Authors: Mateusz J Swierz; Dawid Storman; Robert P Riemsma; Robert Wolff; Jerzy W Mitus; Michal Pedziwiatr; Jos Kleijnen; Malgorzata M Bala Journal: Cochrane Database Syst Rev Date: 2020-03-12
Authors: R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho Journal: Clin Transl Oncol Date: 2019-07-29 Impact factor: 3.405
Authors: Stijn Franssen; Kevin C Soares; Joshua Samuel Jolissaint; Diamantis I Tsilimigras; Stefan Buettner; Sorin Alexandrescu; Hugo Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Georgios A Margonis; Matthew J Weiss; Todd W Bauer; Feng Shen; George A Poultsides; James Wallis Marsh; Andrea Cercek; Nancy Kemeny; T Peter Kingham; Michael D'Angelica; Timothy M Pawlik; William R Jarnagin; Bas Groot Koerkamp Journal: JAMA Surg Date: 2022-07-01 Impact factor: 16.681
Authors: Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447
Authors: Laura Beaton; Henry F J Tregidgo; Sami A Znati; Sharon Forsyth; Matthew J Clarkson; Steven Bandula; Manil Chouhan; Helen L Lowe; May Zaw Thin; Julian Hague; Dinesh Sharma; Joerg-Matthias Pollok; Brian R Davidson; Jowad Raja; Graham Munneke; Daniel J Stuckey; Zainab A Bascal; Paul E Wilde; Sarah Cooper; Samantha Ryan; Peter Czuczman; Eveline Boucher; John A Hartley; Andrew L Lewis; Marnix Jansen; Tim Meyer; Ricky A Sharma Journal: JMIR Res Protoc Date: 2019-10-02
Authors: Jack Martin; Angelica Petrillo; Elizabeth C Smyth; Nadeem Shaida; Samir Khwaja; H K Cheow; Adam Duckworth; Paula Heister; Raaj Praseedom; Asif Jah; Anita Balakrishnan; Simon Harper; Siong Liau; Vasilis Kosmoliaptsis; Emmanuel Huguet Journal: World J Clin Oncol Date: 2020-10-24